The preclinical study reported that the combination of AXL inhibitor and EGFR‐TKIs could be highly potent when given as the initial treatment for AXL‐high expressing EGFR mutated NSCLC.17 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.